New data on Orqis Medical's Cancion® CRS™ to be reported at ACC
Findings will help identify congestive heart failure patients for novel 'rest to recovery' therapy
Lake Forest, Calif. – March 7, 2005 – Newly analyzed research on Orqis Medical's Cancion® CRSTM cardiac recovery system for treating congestive heart failure will be presented at the Annual Scientific Session of the American College of Cardiology (ACC), held in Orlando, Florida (March 6-9).
The data suggests that patients with acutely decompensated chronic heart failure may benefit from the first-of-its-kind Cancion therapy. Based on Orqis Medical's proprietary discoveries in hemodynamic principles, the therapy is designed to create a unique "rest to recovery" environment that enables the failing heart to rest as it continues to function. It represents a significant departure from conventional drug therapy and more invasive blood pumps, which either force the failing heart to work harder, or rest it to the point where it begins to atrophy.
"The patients we analyzed clearly benefited from the Cancion CRS therapy," said Michael Zile, M.D., who analyzed the research data. "By providing continuous aortic flow augmentation, the therapy enabled patients to experience progressive improvement in key measures such as cardiac index and pulmonary capillary wedge pressure."
Dr. Zile's oral presentation (AAC 864-8) is titled "Continuous Aortic Flow Augmentation Using Orqis Cancion Cardiac Recovery System in Patients with Severe Heart Failure: Determinants of the Hemodynamic Response." It will be delivered by Dr. Zile on Wednesday, March 9th at 9:45 a.m. The presentation includes data from 24 patients with congestive heart failure who participated in Orqis Medical's feasibility trials in the US and Europe.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.